On May 19, 2026, Citigroup began coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a Neutral rating. The average one-year price target for the company is set at $105.41 per share, implying a potential upside of 59.71% from its recent closing price of $66.00.
Projected annual revenue for BridgeBio Pharma is $586 million, reflecting a 1.09% increase. The average portfolio weight of institutional investors in BBIO stands at 0.40%. The number of funds reporting positions decreased by 33.57% to 475 over the last quarter, with a total of 213,444,000 shares owned by institutions, marking a slight increase of 0.26%.
Key institutional holders include Kohlberg Kravis Roberts & Co. with 13,261,000 shares (6.77% ownership), and Janus Henderson Group which increased its stake by 16.53% to 13,179,000 shares (6.73% ownership). The put/call ratio for BBIO is currently at 1.15, indicating a bearish sentiment among investors.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
